
Anavasi Diagnostics: Rapid, affordable COVID-19 testing through advanced molecular technology.
Founded with a mission to provide rapid, precise, and affordable diagnostic solutions, Anavasi Diagnostics focuses on the development of advanced molecular diagnostic testing. Their flagship product, the AscencioDx® Molecular Detector, is a portable diagnostic tool that delivers results in as few as 20 minutes. This innovative device is designed for use in various medical settings, including physicians' offices, urgent care clinics, and pharmacies, making it a vital tool in point-of-care facilities.
Anavasi Diagnostics has garnered significant support and recognition, notably being selected by the National Institutes of Health (NIH) for the highly competitive RADx® development program. This endorsement underscores their commitment to advancing healthcare through cutting-edge technology. The company's rapid and efficient diagnostic solutions have made a substantial impact in the medical field, particularly during the COVID-19 pandemic, by enabling timely and accurate testing.

NAT Diagnostics

Instadiagnostics

Minute Molecular Diagnostics

Prompt Diagnostics
prompt-dx.com

Prominex
prominex.com

Molecular Detection

Test Diagnostics

In Diagnostics
indiagnostics.com

Novel Microdevices
noveldx.com

Nanopath
nanopathdx.com

AmplifiDx
amplifidx.com

Burst Diagnostics
burst-dx.com

Diagmetrics
diagmetrics.com

Evanostics

Proxim Diagnostics
proximdx.com
Companies similar to Anavasi Diagnostics include NAT Diagnostics, Instadiagnostics, Minute Molecular Diagnostics and Prompt Diagnostics.
Anavasi Diagnostics was founded in 2021.
Anavasi Diagnostics' headquarters is located in Seattle, WA, US.
Anavasi Diagnostics' most recent funding round was for $2.6M (USD) in January 2022.
As of Jan 12, 2022, Anavasi Diagnostics has raised a total of $23.5M (USD).
Anavasi Diagnostics has 33 employees as of Feb 4, 2024.